PriceTargets.com logo

P3 Health Partners - PIII Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $2.38
  • Forecasted Upside: 1,065.36%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.20 As of 11/20/2024 01:00 AM ET
▼ -0.01 (-4.68%)

This chart shows the closing price for PIII by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New P3 Health Partners Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PIII and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PIII

Analyst Price Target is $2.38
▲ +1,065.36% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for P3 Health Partners in the last 3 months. The average price target is $2.38, with a high forecast of $4.50 and a low forecast of $0.25. The average price target represents a 1,065.36% upside from the last price of $0.20.

This chart shows the closing price for PIII for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 polled investment analysts is to moderate buy stock in P3 Health Partners. This rating has held steady since August 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/20/2024TD CowenLower TargetHold ➝ Hold$0.90 ➝ $0.25
4/1/2024William BlairReiterated RatingOutperform
4/1/2024BTIG ResearchDowngradeBuy ➝ Neutral
3/14/2024Lake Street CapitalLower TargetBuy ➝ Buy$9.00 ➝ $4.50
8/31/2023BTIG ResearchInitiated CoverageBuy$5.00
6/30/2023TD CowenInitiated CoverageMarket Perform
1/4/2022William BlairInitiated CoverageOutperform
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 5 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

P3 Health Partners logo
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.
Read More

Today's Range

Now: $0.20
Low: $0.19
High: $0.25

50 Day Range

MA: $0.38
Low: $0.20
High: $0.50

52 Week Range

Now: $0.20
Low: $0.19
High: $1.78

Volume

2,211,619 shs

Average Volume

479,067 shs

Market Capitalization

$72.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Frequently Asked Questions

What sell-side analysts currently cover shares of P3 Health Partners?

The following Wall Street sell-side analysts have issued reports on P3 Health Partners in the last year: BTIG Research, Lake Street Capital, TD Cowen, and William Blair.
View the latest analyst ratings for PIII.

What is the current price target for P3 Health Partners?

0 Wall Street analysts have set twelve-month price targets for P3 Health Partners in the last year. Their average twelve-month price target is $2.38, suggesting a possible upside of 1,065.4%. Lake Street Capital has the highest price target set, predicting PIII will reach $4.50 in the next twelve months. TD Cowen has the lowest price target set, forecasting a price of $0.25 for P3 Health Partners in the next year.
View the latest price targets for PIII.

What is the current consensus analyst rating for P3 Health Partners?

P3 Health Partners currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PIII.

What other companies compete with P3 Health Partners?

Other companies that are similar to P3 Health Partners include Frontier Investment, Global Consumer Acquisition, Personalis, LifeMD and Sera Prognostics. Learn More about companies similar to P3 Health Partners.

How do I contact P3 Health Partners' investor relations team?

P3 Health Partners' physical mailing address is 2045 W GRAND AVE STUITE B, CHICAGO IL, 60612. The company's listed phone number is 702-910-3950 and its investor relations email address is [email protected]. The official website for P3 Health Partners is foresightacq.com. Learn More about contacing P3 Health Partners investor relations.